Noncoding RNAs in the Regulation of Pluripotency and Reprogramming

Sherstyuk, Vladimir V.; Medvedev, S. P.; Zakian, Suren M.

doi:10.1007/s12015-017-9782-9

Cited by 30 publications

(27 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-coding RNAs were demonstrated to be involved in the modulation of the expression of several genes, which suggested that they may influence the progression of tumors when they regulated tumorrelated genes. 23,24 LOXL1-AS1 was a newly discovered lncRNA first reported by Hauser et al 15 Subsequently, several studies reported its effects on prostate cancer and medulloblastoma. For example, Long et al 17 showed that LOXL1-AS1 expression was distinctly upregulated in prostate cancer and its knockdown suppressed tumor cell proliferation via regulating miR-541-3p and CCND1.…”

Section: Discussionmentioning

confidence: 99%

Serum lncRNA LOXL1‐AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer

Liu¹,

Zhang²

2020

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background: The present study aimed to examine the levels of circulating LOXL1-AS1 in epithelial ovarian cancer (EOC) patients and to analyze its diagnostic and prognostic value. Methods: The levels of LOXL1-AS1 in 185 EOC patients and 43 healthy volunteers were evaluated by a quantitative reverse transcriptase-polymerase chain reaction. The potential of LOXL1-AS1 as a biomarker for EOC diagnosis was determined by receiver-operating characteristic (ROC) curve assays. The associations between clinicopathological parameters and LOXL1-AS1 expression were analyzed using a chisquared test. The influence of LOXL1-AS1 on overall survival was analyzed by the use of Kaplan-Meier. A Cox proportional hazards assays were conducted for the determination of the prognostic value of LOXL1-AS1. Results: The expression of LOXL1-AS1 was dramatically higher in EOC patients compared to healthy controls (p < 0.01). LOXL1-AS1 yielded an area under the ROC curve of 0.843 with 65.3% sensitivity and 68.2% specificity in discriminating highgrade EOC from healthy controls. It was also shown that LOXL1-AS1 expression was associated with advanced FIGO stage (p = 0.004) and positively distant metastasis (p = 0.013). Kaplan-Meier assays revealed that patients with high LOXL1-AS1 expression had a shorter overall survival than those with low expression (p = 0.0006). By performing multivariate assays, LOXL1-AS1 was confirmed to be an independent prognostic factor for predicting the prognosis of EOC patients. Conclusions: We provide evidence indicating that LOXL1-AS1 expression is correlated with a poor clinical outcome in EOC patients and may act as an independent prognostic indicator, as well as a new diagnostic biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum lncRNA LOXL1‐AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer

Liu¹,

Zhang²

2020

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…Some well-researched lncRNAs, including HOTAIR, MALAT-1, HULC, and H19 have been proven to act as oncogenes or tumor suppressor genes and correlate with drug resistance [44][45][46][47]. LncRNAs regulate gene expression at the epigenetic, transcriptional, and posttranscriptional levels [32-34, 48, 49], and also regulate the reprogramming of induced pluripotent stem cells [50]. A few studies found that compared with healthy individuals, MALAT1 and MEG3 lncRNAs are overexpressed in patients with MM [51].…”

Section: Discussionmentioning

confidence: 99%

“…The clinical characteristics of each patient were also established and recorded. Three patients were male, and the median age was 52 (48)(49)(50)(51)(52)(53)(54)(55)…”

Section: Patients and Cell Samplesmentioning

confidence: 99%

Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma

Ying

et al. 2019

BMC Med Genomics

View full text Add to dashboard Cite

Background: Long noncoding RNAs (lncRNAs) are involved in a wide range of biological processes in tumorigenesis. However, the role of lncRNA expression in the biology, prognosis, and molecular classification of human multiple myeloma (MM) remains unclear, especially the biological functions of the vast majority of lncRNAs. Recently, lncRNAs have been identified in neoplastic hematologic disorders. Evidence has accumulated on the molecular mechanisms of action of lncRNAs, providing insight into their functional roles in tumorigenesis. This study aimed to characterize potential lncRNAs in patients with MM. Methods: In this study, the whole-transcriptome strand-specific RNA sequencing of samples from three newly diagnosed patients with MM was performed. The whole transcriptome, including lncRNAs, microRNAs, and mRNAs, was analyzed. Using these data, MM lncRNAs were systematically analyzed, and the lncRNAs involved in the occurrence of MM were identified. Results: The results revealed that MM lncRNAs had distinctive characteristics different from those of other malignant tumors. Further, the functions of a set of lncRNAs preferentially expressed in MM were verified, and several lncRNAs were identified as competing endogenous RNAs. More importantly, the aberrant expression of certain lncRNAs, including maternally expressed gene3, colon cancer-associated transcript1, and coiled-coil domaincontaining 26, as well as some novel lncRNAs involved in the occurrence of MM was established. Further, lncRNAs were related to some microRNAs, regulated each other, and participated in MM development. Conclusions: Genome-wide screening and functional analysis enabled the identification of a set of lncRNAs involved in the occurrence of MM. The interaction exists among microRNAs and lncRNAs.

show abstract

“…Noncoding RNAs are critical players in organizing the regulatory networks that establish or remove roadblocks in this reprogramming process 14–17 . Long non-coding RNAs (lncRNAs), which are >200 nucleotides in length and lack apparent open reading frames, may control gene activity at a transcriptional level via either cis or trans mechanisms 18 , 19 .…”

Section: Background and Summarymentioning

confidence: 99%

Combined RNA-seq and RAT-seq mapping of long noncoding RNAs in pluripotent reprogramming

Jia

Wang

et al. 2018

Sci Data

View full text Add to dashboard Cite

Pluripotent stem cells hold great investigative potential for developmental biology and regenerative medicine. Recent studies suggest that long noncoding RNAs (lncRNAs) may function as key regulators of the maintenance and the lineage differentiation of stem cells. However, the underlying mechanisms by which lncRNAs affect the reprogramming process of somatic cells into pluripotent cells remain largely unknown. Using fibroblasts and induced pluripotent stem cells (iPSCs) at different stages of reprogramming, we performed RNA transcriptome sequencing (RNA-Seq) to identify lncRNAs that are differentially-expressed in association with pluripotency. An RNA reverse transcription-associated trap sequencing (RAT-seq) approach was then utilized to generate a database to map the regulatory element network for lncRNA candidates. Integration of these datasets can facilitate the identification of functional lncRNAs that are associated with reprogramming. Identification of lncRNAs that regulate pluripotency may lead to new strategies for enhancing iPSC induction in regenerative medicine.

show abstract

Noncoding RNAs in the Regulation of Pluripotency and Reprogramming

Cited by 30 publications

References 161 publications

Serum lncRNA LOXL1‐AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer

Serum lncRNA LOXL1‐AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer

Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma

Combined RNA-seq and RAT-seq mapping of long noncoding RNAs in pluripotent reprogramming

Contact Info

Product

Resources

About